Activation of AMP-activated kinase as a strategy for managing autosomal dominant polycystic kidney disease

Medical Hypotheses

Volumn 73, Issue 6, 2009, Pages 1008-1010

  McCarty, Mark F ^a   Barroso Aranda, Jorge ^a   Contreras, Francisco ^a  

^a Oasis of Hope Hospital   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; B RAF KINASE; BERBERINE; CALCIUM ION; CHLORIDE ION; CYCLIC AMP; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; POLYCYSTIN 1; POLYCYSTIN 2; PROTEIN KINASE B; RAPAMYCIN; RAS PROTEIN; RHEB PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUBERIN; VASOPRESSIN ANTAGONIST;

ARTICLE; CALCIUM CELL LEVEL; CHLORIDE TRANSPORT; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; INFECTIOUS DIARRHEA; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BERBERINE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ENZYME ACTIVATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; METFORMIN; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROTEIN-SERINE-THREONINE KINASES;

BACTERIA (MICROORGANISMS); MAMMALIA;

EID: 70449719320     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.05.043     Document Type: Article

References (47)

1. Sutters M., and Germino G.G. Autosomal dominant polycystic kidney disease: molecular genetics and pathophysiology. J Lab Clin Med 141 2 (2003) 91-101
2. Gattone V.H., Wang X., Harris P.C., and Torres V.E. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9 10 (2003) 1323-1326
3. Kip S.N., Hunter L.W., Ren Q., Harris P.C., Somlo S., Torres V.E., et al. [Ca2+]i reduction increases cellular proliferation and apoptosis in vascular smooth muscle cells: relevance to the ADPKD phenotype. Circ Res 96 8 (2005) 873-880
4. Yamaguchi T., Hempson S.J., Reif G.A., Hedge A.M., and Wallace D.P. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 17 1 (2006) 178-187
5. Hanaoka K., Devuyst O., Schwiebert E.M., Wilson P.D., and Guggino W.B. A role for CFTR in human autosomal dominant polycystic kidney disease. Am J Physiol 270 1 Pt 1 (1996) C389-C399
6. Davidow C.J., Maser R.L., Rome L.A., Calvet J.P., and Grantham J.J. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro. Kidney Int 50 1 (1996) 208-218
7. Li H., Findlay I.A., and Sheppard D.N. The relationship between cell proliferation, Cl-secretion, and renal cyst growth: a study using CFTR inhibitors. Kidney Int 66 5 (2004) 1926-1938
8. Tanner G.A., McQuillan P.F., Maxwell M.R., Keck J.K., and McAteer J.A. An in vitro test of the cell stretch-proliferation hypothesis of renal cyst enlargement. J Am Soc Nephrol 6 4 (1995) 1230-1241
9. Torres V.E. Vasopressin antagonists in polycystic kidney disease. Kidney Int 68 5 (2005) 2405-2418
10. Nagao S., Nishii K., Katsuyama M., Kurahashi H., Marunouchi T., Takahashi H., et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 17 8 (2006) 2220-2227
11. Shillingford J.M., Murcia N.S., Larson C.H., Low S.H., Hedgepeth R., Brown N., et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 103 14 (2006) 5466-5471
12. Tao Y., Kim J., Schrier R.W., and Edelstein C.L. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16 1 (2005) 46-51
13. Wahl P.R., Serra A.L., Le H.M., Molle K.D., Hall M.N., and Wuthrich R.P. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 21 3 (2006) 598-604
14. Kwiatkowski D.J., and Manning B.D. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 14 2 (2005) R251-R258
15. Rolfe M., McLeod L.E., Pratt P.F., and Proud C.G. Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2). Biochem J 388 Pt 3 (2005) 973-984
16. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., and Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121 2 (2005) 179-193
17. Buhaescu I., Izzedine H., and Covic A. Sirolimus - challenging current perspectives. Ther Drug Monit 28 5 (2006) 577-584
18. Reynolds N.J., and Al-Daraji W.I. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol 27 7 (2002) 555-561
19. Motoshima H., Goldstein B.J., Igata M., and Araki E. AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574 Pt 1 (2006) 63-71
20. Kimball S.R. Interaction between the AMP-activated protein kinase and mTOR signaling pathways. Med Sci Sports Exerc 38 11 (2006) 1958-1964
21. Zou M.H., Kirkpatrick S.S., Davis B.J., Nelson J.S., Wiles W.G., Schlattner U., et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem 279 42 (2004) 43940-43951
22. Hawley S.A., Gadalla A.E., Olsen G.S., and Hardie D.G. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51 8 (2002) 2420-2425
23. Musi N., Hirshman M.F., Nygren J., Svanfeldt M., Bavenholm P., Rooyackers O., et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51 7 (2002) 2074-2081
24. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108 8 (2001) 1167-1174
25. Lee M.J., Feliers D., Mariappan M.M., Sataranatarajan K., Mahimainathan L., Musi N., et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 292 2 (2007) F617-F627
26. Hallows K.R., Raghuram V., Kemp B.E., Witters L.A., and Foskett J.K. Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase. J Clin Invest 105 12 (2000) 1711-1721
27. Hallows K.R., McCane J.E., Kemp B.E., Witters L.A., and Foskett J.K. Regulation of channel gating by AMP-activated protein kinase modulates cystic fibrosis transmembrane conductance regulator activity in lung submucosal cells. J Biol Chem 278 2 (2003) 998-1004
28. Hallows K.R., Kobinger G.P., Wilson J.M., Witters L.A., and Foskett J.K. Physiological modulation of CFTR activity by AMP-activated protein kinase in polarized T84 cells. Am J Physiol Cell Physiol 284 5 (2003) C1297-C1308
29. Walker J., Jijon H.B., Churchill T., Kulka M., and Madsen K.L. Activation of AMP-activated protein kinase reduces cAMP-mediated epithelial chloride secretion. Am J Physiol Gastrointest Liver Physiol 285 5 (2003) G850-G860
30. Hallows K.R. Emerging role of AMP-activated protein kinase in coupling membrane transport to cellular metabolism. Curr Opin Nephrol Hypertens 14 5 (2005) 464-471
31. Towler M.C., and Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100 3 (2007) 328-341
32. Vitale C., Mercuro G., Cornoldi A., Fini M., Volterrani M., and Rosano G.M. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 258 3 (2005) 250-256
33. Jadhav S., Ferrell W., Greer I.A., Petrie J.R., Cobbe S.M., and Sattar N. Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 48 5 (2006) 956-963
34. de Aguiar L.G., Bahia L.R., Villela N., Laflor C., Sicuro F., Wiernsperger N., et al. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 29 5 (2006) 1083-1089
35. McAfee A.T., Koro C., Landon J., Ziyadeh N., and Walker A.M. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 16 7 (2007) 711-725
36. Wang D., Iversen J., Wilcox C.S., and Strandgaard S. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 64 4 (2003) 1381-1388
37. Zhu B., and Ahrens F.A. Effect of berberine on intestinal secretion mediated by Escherichia coli heat-stable enterotoxin in jejunum of pigs. Am J Vet Res 43 9 (1982) 1594-1598
38. Rabbani G.H., Butler T., Knight J., Sanyal S.C., and Alam K. Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae. J Infect Dis 155 5 (1987) 979-984
39. Berberine. Altern Med Rev 2000; 5(2): 175-177.
40. Ni Y.X. Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research. Zhong Xi Yi Jie He Za Zhi 8 12 (1988) 711-713 707
41. Tang L.Q., Wei W., Chen L.M., and Liu S. Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J Ethnopharmacol 108 1 (2006) 109-115
42. Lee Y.S., Kim W.S., Kim K.H., Yoon M.J., Cho H.J., Shen Y., et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55 8 (2006) 2256-2264
43. Cheng Z., Pang T., Gu M., Gao A.H., Xie C.M., Li J.Y., et al. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim Biophys Acta 1760 11 (2006) 1682-1689
44. Brusq J.M., Ancellin N., Grondin P., Guillard R., Martin S., Saintillan Y., et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 47 6 (2006) 1281-1288
45. Spangler B.D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev 56 4 (1992) 622-647
46. Thiagarajah J.R., and Verkman A.S. CFTR pharmacology and its role in intestinal fluid secretion. Curr Opin Pharmacol 3 6 (2003) 594-599
47. Chen L., Stacewicz-Sapuntzakis M., Duncan C., Sharifi R., Ghosh L., van Breemen R., et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 93 24 (2001) 1872-1879